Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics, Inc. is progressing with the use of its drug rusfertide for the treatment of polycythemia vera in a phase 3 study. The company expects to complete enrollment of the VERIFY study by Q1 2024 and release results in 2024. Protagonist Therapeutics has enough cash to fund its operations through the end of 2025 and could earn $200 million in milestone payments.

Protagonist: Rusfertide Has Potential For Patients With Polycythemia Vera

Estimated cash runway now extended through Q1 2026 NEWARK, CA / ACCESSWIRE / August 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has received approximately $34.4 million in proceeds from the exercise of warrants to purchase 2.75 million shares of the Company's Common Stock. The warrants were issued in connection with an August 2018 equity financing and expired on August 8, 2023.

Protagonist Receives $34 Million from Warrant Exercises

Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagonist oral peptide drug candidate for the treatment of moderate-to-severe plaque psoriasis, presented at the World Congress of Dermatology. JNJ-2113 now advances toward a Phase 3 study in moderate-to-severe psoriasis and a Phase 2b study in ulcerative colitis.

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Brainstorm Cell Therapeutics

Cosmos Holdings

Sharecare

Beyond Air Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Phase 2b FRONTIER 1 data presentation at World Congress of Dermatology highlights that a greater proportion of patients achieved 75, 90 and 100 percent improvement in skin clearance at week 16 in comparison to placebo Phase 3 development in moderate-to-severe plaque psoriasis and Phase 2b development in ulcerative colitis are planned by Janssen NEWARK, CA / ACCESSWIRE / July 4, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") today announced positive topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor (IL-23R) antagonist JNJ-2113 (formerly PN-235) in adult patients with moderate-to-severe plaque psoriasis (PsO)[i] presented at World Congress of Dermatology in Singapore. The trial achieved all primary and secondary efficacy endpoints.

Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis

Protagonist Therapeutics (PTGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why

The consensus price target hints at a 25.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know

Ligand Pharmaceuticals

Mesoblast

Puma Biotechnology

Vaxcyte

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.

5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good

Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going

NEWARK, CA / ACCESSWIRE / June 9, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai, provided a press briefing this morning on the late-breaking oral presentation abstract LB2710: Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide - Blinded Randomized Withdrawal Results of the REVIVE Study at the European Hematology Association (EHA) 2023 Congress. The study results will be presented in detail by Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai, on Sunday, June 11, 2023 at 9:45-10:00 CEST.

Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Ru

NEWARK, CA / ACCESSWIRE / June 6, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that a late-breaking abstract featuring blinded, randomized withdrawal data from the rusfertide (PTG-300) REVIVE Phase 2 study in polycythemia vera (PV) has been accepted for oral presentation at the European Hematology Association (EHA) 2023 Congress: Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera with the Hepcidin Mimetic, Rusfertide - Blinded Randomized Withdrawal Results of the REVIVE Study: - Late Breaking Oral Presentation: Presented by Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai on Sunday, June 11, 9:45 - 10:00 CEST As previously announced, EHA will also feature two additional presentations from the Company's rusfertide peptide therapeutic development program, including new data and updates in polycythemia vera. Rusfertide (PTG-300) Improves (PV)-related Symptoms: - Presented by Andrew Kuykendall, MD, Moffitt Cancer Center on Friday, June 9, 18:00 - 19:00 CEST Pharmacokinetic and Pharmacodynamic Effects of Rusfertide in Polycythemia Vera: Results from an Ongoing Phase 2 Study in Patients with Elevated Hematocrit Values: - Presented by Marina Kremyanskaya, MD, PhD, Icahn School of Medicine at Mount Sinai on Friday, June 9, 18:00 - 19:00 CEST "We are very pleased to showcase a breadth of data at EHA demonstrating the tremendous promise for rusfertide to change the polycythemia vera treatment paradigm by potentially eliminating the need for phlebotomy, providing improvement of symptoms associated with PV, controlling erythrocytosis and ultimately achieving the treatment goal of maintaining hematocrit under 45% in step with current NCCN and ELN Clinical Practice Guidelines," said Arturo Molina, MD, MS, Chief Medical Officer, Protagonist Therapeutics.

Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress

NEWARK, CA / ACCESSWIRE / June 1, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.

Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 38% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01%

The stock of Protagonist Therapeutics, Inc. has more than doubled so far this year due to progress on a couple of fronts. Can the rally in the shares continue in 2023?

Protagonist Therapeutics Sees Steady If Bumpy Progress

Protagonist continues to quietly progress its pipeline, relying mainly on the polycythemia vera story to drive its business efforts. An ongoing phase 3 study will be the critical readout, but that doesn't mean that you need to wait for it.

Protagonist Therapeutics: All Quiet Heading Into An Important H2 2023

Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases NEWARK, Calif. , May 12, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), on Phase 1 and preclinical studies of JNJ-2113 (formerly PN-235), presented by Janssen and co-authored with Protagonist, as an oral presentation at the International Societies for Investigative Dermatology (ISID) 2023 meeting in Tokyo, Japan.

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V.

Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference

NEWARK, Calif. , May 11, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that additional data from the REVIVE study of rusfertide in polycythemia vera will be presented in two posters at the annual Congress of the European Hematology Association (EHA), taking place June 8-11, 2023 in Frankfurt, Germany and virtually through June 15, 2023.

Protagonist Therapeutics Announces Presentations at the 2023 Annual Congress of the European Hematology Association

Shares of PTGX stock briefly broke out Friday after Protagonist said it plans to soon present new test results for its psoriasis drug. The post Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm appeared first on Investor's Business Daily.

Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm

Announced positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), a first-in-class oral peptide for the treatment of moderate-to-severe plaque psoriasis; additional data to be shared at medical conferences beginning in Q2 2023 Announced positive topline results from the randomized withdrawal portion of the Phase 2 REVIVE study of rusfertide in polycythemia vera (PV), with additional data to be shared at medical conferences beginning in Q2 2023 Extended cash runway through end of 2025 with the completion of an underwritten public offering of 5,750,000 shares with net proceeds of $108.1 million after deducting underwriting discounts and commissions NEWARK, Calif. , May 4, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update

Protagonist Therapeutics could become a buyout target. The company's lead therapy is coming off promising results as a cancer treatment.

Why Shares of Protagonist Therapeutics Rose This Week

NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share. Gross proceeds to Protagonist from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and offering expenses.

Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock

NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the securities to be sold in the offering are being offered by Protagonist.

Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study Highly statistically significant results from the randomized withdrawal portion of the REVIVE study of rusfertide in polycythemia vera, achieving its primary endpoint of proportion of responders on rusfertide versus placebo (p=0.0003) NEWARK, CA / ACCESSWIRE / March 15, 2023 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "The positive FRONTIER 1 JNJ-2113 (PN-235) data recently reported represents a scientific breakthrough with the potential to transform the treatment landscape for moderate-to-severe plaque psoriasis with oral targeted therapy.

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Rusfertide met the study's primary endpoint, with a statistically significant higher number of responders on rusfertide versus placebo (p=0.0003) Rusfertide continues to be generally well tolerated with no new safety signals NEWARK, CA / ACCESSWIRE / March 15, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company"), today announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE, a study evaluating rusfertide, a subcutaneous injectable hepcidin mimetic, in patients with polycythemia vera (PV). Subjects receiving rusfertide achieved highly statistically significant improvements versus placebo in the primary endpoint.

Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera

News for Protagonist Therapeutics Stock (PTGX)